Benzinga | Apr 13, 2021 08:04AM EDT

ADMA Biologics Announces Poster Presentation Highlighting Pharmacoeconomic Burden of HIV and HBV Infection in Sexual Assault Patients at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting

ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting ("AMCP") taking place April 12-16, 2021.

"Current CDC guidelines for post-exposure prophylaxis of suspected Hepatitis B infection ("HBV") offer no intervention for sexual assault victims with perpetrators of unknown Hepatitis B surface antigen status," said Adam Grossman, President and Chief Executive Officer of ADMA. "HBV is significantly more infectious than is HIV, and can be transmitted by any bodily fluid, and amounts to a roughly equivalent cost burden for the US healthcare system. Our analysis suggests that amending CDC guidelines in this at-risk population for HBV to mirror those of HIV and specifically mandating a Hepatitis B Globulin intervention like ADMA's Nabi-HB hyperimmune, will provide a cost-effective strategy for prophylactic seroprotection of these vulnerable patients. It is our hope that lobby groups advocating on behalf of at-risk patients will leverage this analysis to convey to policymakers that failing to address this patient population, and harmonizing treatment guidelines between HIV and HBV, may have considerable clinical and cost implications for the US healthcare system."